Business
GB Sciences One of Ten Companies Named in Important New Canadian Research Publication
GB Sciences One of Ten Companies Named in Important New Canadian Research Publication.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n\n\nGB Sciences One of Ten Companies Named in Important New Canadian Research Publication\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nGB Sciences One of Ten Companies Named in Important New Canadian Research Publication\nCorporate strategy dedicated to scientific medical research, a viable drug development pipeline and a strong Intellectual Properties Patent Portfolio are cited as the key differentiating factors.\nPR Newswire\nLAS VEGAS, July 9, 2018\n\n\n\nLAS VEGAS, July 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) was named as one of the ten select cannabis companies in North America according to a study conducted by a leading investment banking firm in their June 20, 2018 Industry Report on Medical Cannabis. The report included deep research and analyst coverage on 31 public and 31 private cannabis companies from the US and Canada. GB Sciences was the only U.S. publicly traded company to make the list of ten companies.\n\n\n \n \n\n \nThe sixty-two target Companies were evaluated on the following criteria:\n\n\"Through our research, we have evaluated the clinical approach and fundamental technologies employed by a broad spectrum of companies participating in the clinical cannabis ecosystem. Here, we collect a group of 10 companies that we believe have the potential to capture the massive opportunities that lie in wait for those that focus on:\n\n\nThe consistent, large-scale production of high-quality cannabinoids;\nThe development of finely controlled, deeply studied cannabinoid drug formulations; and\nThe generation of gold standard clinical data supporting the registration of proprietary cannabinoid formulations to address specific clinical indications.\"\nAnalyst Coverage for GB Sciences Inc. (GBLX-OTC):\"GB Sciences is a Nevada-based medical and recreational cannabis producer that is already generating revenue from its Las Vegas operations. What excites us most about GB, however, is its clinical discovery program. Chief Science Officer, Dr. Andrea Small-Howard, is using in silico data analysis to identify indications with well-established...